MEETING GUIDE - WHO | World Health Organization · MEETING GUIDE. CONTENTS Welcome to ... •...

TRANSPARENCY F R CHANGE

Good Governance For Medicines Global Stakeholders Meeting3-5 December 2007, Bangkok, Thailand

The Ministry of Public Health, Thailand

MEETINGGUIDE

CONTENTS

Welcome to the Good Governance for Medicines Stakeholders Meeting

• WelcomebyWorldHealthOrganization 7

• WelcometoBangkok 9

• WelcometoTheMontienHotelBangkok 11

Professional Programme

• MeetingAgenda 13

• PlenarySessions’Objectives 18

• WorkshopSessions’Objectives 22

Networking Events

• WelcomeCocktail 29

• OffSiteDinner 29

Speakers

• SpeakerProfilesandPhotos 31

EvaluationForm 63

Notes 71

WELCOME

7

WELCOMEBYTHEWORLDHEALTHORGANIZATION

DearParticipants,

IwouldliketopersonallywelcomeyoutotheGlobalStakeholdersmeetingoftheWHO

GoodGovernanceforMedicinesprogramme.

Thisistheprogramme's2ndglobalstakeholdersmeetingthatWHOhasorganized,

andwearedelightedtoseesomanyofyouhereinBangkok.Thisisarealsignthat

transparency in the pharmaceutical sector is an area of increasing interest for our

stakeholdersandthatmoreandmorecountriesarekeentoworkinthischallenging,

butrewardingarea.

Thethemeofthemeetingis"TransparencyforChange".Icanpromiseyouthat

thenextthreedayswillbefulloflearningandnetworkingopportunitiesforyouall,

withtheopportunitytoreviewexperiencesandtolearnfromeachother.Wehave

animpressivelineupofeminentspeakerswhowillsharetheirinsightsintotoday’s

issuesandchallenges.Ourspeakerswillnotonlyincreaseourknowledgeoftheworld

ofgoodgovernanceingeneral,andofthemedicinesareainparticular,butourinten-

tionisthattheywillalsomotivateustoincreaseoureffortstoimprovethesituation

inthepharmaceuticalsectorwhenweleaveBangkokandreturntoourvariouswork

settings.Thegoaliseventuallytoofferaprocessforlong-lastingchange-forallof

ustomobilizea"callforaction"tomeetthechallengesahead,andultimatelytohelp

makequalityessentialmedicinesaccessibleandaffordableforall.

Having launched itsprogramme in2004,WHOremainscommittedtopromoting

goodgovernanceformedicinesinthefuture.Itwilldosobyfurtherrefiningitspolicy

andtechnicalguidanceandbyprovidingtechnicalsupporttocountrieswhorequestit.

WHOwillalsocontinuetoactasafacilitatortobringallthekeystakeholderstogether

onaregularbasistoprovidethisplatformtoexchangeexperiencesandnetwork.

Wewouldliketothankourhosts,theThaiMinistryofPublicHealth,aswellas

WHO’sCountryOfficeinBangkokandtheWHORegionalOfficeforSouth-EastAsiafor

8

theirvaluable support.Theconferencewouldnothavebeenpossiblewithout their

dedicationandhardworkinthelastfewmonths.

Andfinally,Ithankeveryoneforcoming-panellists,moderatorsandparticipants.

Ihopeyouhaveanenjoyableandrewardingtimewithus.Ifyouneedassistanceof

anykind,pleasecontactoneofourteammembers,whowillbemakingthemselves

knowntoyou.

Ilookforwardtomeetingyou,

DrHansV.Hogerzeil

Director

MedicinesPolicyandStandards

WorldHealthOrganization

8

9

Didyouknowthattherearemorethan10millionpeoplelivinginBangkok?

Or,didyouknowthatthelocalscallBangkok“KrungThep”whichmeanstheCityof

Angels?

Thailand’scapitalcity,Bangkok,haschangedintoamodern,excitingandsophisti-

catedcity.Itofferstovisitorsnotonlythecosmopolitanamenitiestheywouldexpect

fromotherbigcities,butalsoauniquetreasuretroveofculturalattractions.Bangkok

offersvisitorstheopportunitytoexperienceafascinatingglimpseofThailand’sgentle

cultureamidstthebustleofagreatanddynamicmetropolis.

Interestingfacts—didyouknowthat...?• Siamchangeditsnamein1939toThailand,meaning“landofthefree”.

• 75%ofthepeoplelivinginThailandareThai,14%areChineseand11%other

nationalities.

• thereare400glitteringBuddhisttemplesinBangkok.

• thereare3.8%MuslimsinThailand,0.1Hindus,0.5%Christians,0.6%other

religionsand95%Buddhists.

• BangkokhasdevelopedintooneofthemostpopularshoppinglocationsinAsia.

• Bangkokwasfoundedin1782bythefirstmonarchofthepresentChakridynasty

anditistodayaconstitutionalmonarchy.

• Skytrainfarescostbetween10Bahtand40Bahtperpersondependingonthe

distance,aboutonethirdthecostofacomparabletaxiride.

• Thailandhas3290kmofcoastline.

• taxisoutnumberprivatecars2:1inBangkokandmostjourneyscanbecompleted

forwellunder100Baht.Makesureyoutakeagenuinetaxiwithataximeter.

• oneUSdollarisequaltoapproximately30Baht.

• theThailanguageissimilartoTai,thelanguagespokenbythepeoplewholivein

SouthernChina.

• KingBhumibolAdulyadej,thebelovedkingofThailand,isgoingtobe80years

oldonDecember5th.HewasborninCambridge,Massachusetts,USA,andedu-

catedinLausanneinSwitzerland.

WELCOMETOTHEKINGDOMOFTHAILANDANDITSCAPITALBANGKOK

10

YourSmallEnglish–ThaiDictionary:

ENGLISH THAI

Goodmorning,Goodevening,Goodafternoon,Good

night,Hello

sa-wat-dee

Hello(malespeaker) sawatdeekrup

Hello(femalespeaker) sawatdee kaa

Yes chai

No mai

Mr./Miss/Mrs. khun

Howareyou? sabaideereu

Fine thanks sabaidee

Whereistherestroom? hongnamyooteenai

Iamgoingto... chan-cha-pai...

Stop yut

Howmuchdoesthiscost? nee tao-rai

Whatisthis? nee arai

Veryexpensive paengmaag

Anydiscount? lot-ra-kha-dai-mai

Pleasewrapitforme ho-hai-duai

Thebillplease geptaang

Pleasespeakslowly prot-phut-cha-cha

VeryGood di-mak

Not Good mai-di

Goodbye la gon

Seeyouagain laewphobganmai

Good luck kor hai chok dee

Sorry/excuseme kor thoad

10

11

WELCOMETOTHEMONTIENHOTELBANGKOK

TheMontienHotelBangkokislocatedintheheartofBangkok'smajorbusinessand

entertainmentdistrict,withineasywalkingdistanceofmanyoffices,shopsandnight-

spots.JustfiveminutesawayistheneareststationoftheMassTransitSystem,which

providesrapidaccesstootherpartsofthecity.Offering475roomsandsuites,includ-

ingExecutiveFloorswithprivatelounge,meetingroomsandfullyequippedbusiness

centre,thehotelisperfectlysituatedforboththebusinesstravellerandtheleisure

visitortoBangkok.

ThehotelislocatedonSurawongseRoad,yourbusinessaddressintheheartofthecity

withthemostflexiblecombinationofsuperioraccommodationandbusinessfacilities

tomeetyoureverydemand.MontienHotelBangkokisproudtoofferawidevariety

ofcuisineincludingaChineseandaEuropeanrestaurantaswellasa24-hoursInter-

nationalCoffeeShop.

ItiswithdelightthatthehotelwelcomesallparticipantstotheGoodGovernancefor

MedicinesStakeholdersMeeting,3-5thDecember2007.

HotelAddress:

54SurawongseRoad,Bangkok10500,Thailand.

Tel.:(662)233-7060-9

http://www.montien.com/bangkok/

13

PROGRAMME

14

TIME DAY1

08.00-08.45 Registration

08.45-09.00 OfficialOpeningbytheThaiMinistryofPublicHealth

09.00-10.15 Plenary Session 1:

Think transparency! Good Governance in the pharmaceutical sector.Room:RajmontienIV,MezzanineFacilitator:Dr.HansHogerzeil,WorldHealthOrganization

Panelists:Promoting Good Governance in the Pharmaceutical Sector, a Global ExperienceDr.GuitelleBaghdadi-Sabeti,WorldHealthOrganization

Good Governance for Medicines Programme: the Thai ExperienceDr.ChanvitTharathep,MinistryofPublicHealth,Thailand

Toward Scientific Drug Administration Mr.ChangyuanLin, StateFoodandDrugAdministration,People’sRepublicofChina

Transparency in the Governance of Bulgaria’s Pharmaceutical System – results of a case studyMrs.GerganaAndre,InternationalHealthcareandHealthInsuranceInstitute,Bulgaria

10.15-10.30 Questionsandplenarydiscussions

10.30-11.00 CoffeeBreak


The root of corruption. Understanding the issues to cure it!Room:RajmontienIV,MezzanineFacilitator:Dr.CliveOndari,WorldHealthOrganization

Panelists:Governance and Corruption: the Gray Area of Policy Dr.MaureenLewis,TheWorldBank

Fighting Corruption - Challenges and ThreatsMr.MartinKreutner,FederalBureauforInternalAffairs,Austria

Systems, Attitudes, and Action as Root Causes of Corruption Dr.StevenRood,AsiaFoundation,Philippines

Transparency International Global Corruption Report 2006TransparencyInternationalSecretariat,representativetobeannounced


15

12.30-14.00 Lunch:MontiRestaurantatthehotel

14.00-15.30 Workshops1aand1b:SeminarI&SeminarII,6thFloorBRIDGINGTHERESEARCHGAP–whatdowestillneedtoknow,andhowdowegoaboutit?

14.00-15.30 Workshops2aand2b:SeminarIII&IV,6thFloorMAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY–how?

14.00-15.30 Workshops3aand3b:SeminarV&VI,7thFloorESTABLISHINGANATIONALGGMTASKFORCE–whatarethechallengesahead?

14.00-15.30 Workshops4aand4b:SeminarVII&VIII,7thFloorJOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES–whatworks,whatdoesn’t?


16.00-17.00 Presentations/FeedbackfromWorkshops

19.00-21.00 WelcomeReception

TIME DAY2


Practicing transparency! Good Governance in the health sector.Room:Montienthip,MezzanineFacilitator:Dr.HansHogerzeil,WorldHealthOrganization

Panelists:Good and Bad Practices in Good Governance and What Can Be Done toPromote Good Governance Dr.MaureenLewis,TheWorldBank

Protecting Healthcare Systems Against Fraud so that They CanBetter Protect the Health of Citizens Mr.JimGee,KPMGForensic,UnitedKingdom

Detecting and Solving System WeaknessesMr.PaulVincke,EuropeanHealthcareFraudandCorruptionNetwork,Belgium

Promoting Good Governance in Medicines: Industry’s RoleDr.EricNoehrenberg, International Federation of Pharmaceutical Manufacturers&Associations,Switzerland



16


Keeping it together! The basic ingredients for ensuring Good

Governance.Room:Montienthip,MezzanineFacilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup

Panelists:The Ethical Dimension of Good Governance Dr.EloyAnello,NúrUniversity,Bolivia

Promoting Good Governance, the Experience of the Ministry of Health in GermanyDr.SonjaFüsser,MinistryofHealth,Germany

A National Strategy for Ensuring Good GovernanceMrs.FatumaSichale,Anti-CorruptionCommission,Kenya


12.30-14.00 Lunch:MontiRestaurant(Wewillcollectquestionsforthenextmorning’ssession.)

14.00-15.30 Workshops5aand5b:SeminarI&SeminarII,6thFloorCANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?–howdowebringtransparencytothegreyzone?

14.00-15.30 Workshops6aand6b:SeminarIII&IV,6thFloorDEFININGINTEGRITY–howdoweraisethestandardsandmotivatepermanentchange?

14.00-15.30 Workshops7aand7b:SeminarV&VI,7thFloorWHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?•whoaretheplayers?•whatwillbetheimpactonpublichealth?

14.00-15.30 Workshops8aand8b:SeminarVII&VIII,7thFloorSERVINGTRANSPARENCY!HowcanWHObeofbetterservicewhenfacilitatingGGMprogrammeimplementation?Giveideasandfeedback.


16.00-17.00 Presentations/FeedbackfromWorkshops

18.30-21.00 Off Site Networking Dinner

17

TIME DAY3


Questioning transparency.

Our panelists respond to you!Room:Montienthip,MezzanineFacilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup



Rolling out transparency. What is your role?Room:Montienthip,MezzanineFacilitator:Dr.CliveOndari,WorldHealthOrganization

Panelists:USAID Support for Good Governance in MedicinesMr.AnthonyBoni,USAID,UnitedStatesofAmerica

Civil Society Organizations: What is Their Role in Promoting Transparency?Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines

How can the academia support the global efforts to promote transparency and good governance?Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand

The role of development institutions in promoting good governance in the pharmaceutical sectorDr.ZafarMirza,WHORegionalOfficefortheEasternMediterranean


OfficialClosingbytheThaiMinistryofPublicHealth

12.30-14.00 Lunch:MontiRestaurant

18

Session1:Thinktransparency!GoodGovernanceinthepharmaceuticalsector.Facilitator:Dr.HansHogerzeil,WHO,Switzerland

Panellists:

•Dr.GuitelleBaghdadi-Sabeti,WHO,Switzerland

•Dr.ChanvitTharathep,MinistryofPublicHealth,Thailand

•Mr.ChangyuanLin,StateFoodandDrugAdministration,People'sRepublicofChina

•Mrs.GerganaAndre,InternationalHealthcareandHealthInsuranceInstitute,Bulgaria

Theimportanceoftransparencyandaccountabilityinpharmaceuticalsystemsis in-

creasinglyrecognizedbythevariouskeyplayersatthecountryandinternationallev-

els.Recentinitiatives,whetheraimingatimprovinggoodgovernanceortacklingcor-

ruptionperse,provideconcreteevidence.Theseincludeglobalinitiativessuchasthe

WHOGoodGovernanceforMedicinesprogramme,aswellaspracticalcountryapplica-

tions.Duringthissession,experiencesinreflectingonandpromotingtransparencywill

beshared,togetherwithlessonslearnttodate.

Session2:Therootofcorruption.Understandingtheissuestocureit!Facilitator:Dr.CliveOndari,WHO,Switzerland

Panellists:

•Dr.MaureenLewis,WorldBank

•Mr.MartinKreutner,BureauofInternationalAffairs,FederalMinistryofInterior,Austria

•TransparencyInternationalSecretariat,representativetobeannounced

•Mr.StevenRood,AsiaFoundation,Philippines

Corruptionisaworld-wideproblem,existinginbothhigh-andlow-incomecountries.

Itisrecognizedasthesinglegreatestobstacletosocialandeconomicdevelopment.

Corruption erodes the institutional capacity of governments, increases the cost of

PLENARYSESSIONS’OBJECTIVES

19

businessandisdemeaningforpoorpeople,worseningtheirfinancialburden.Thisses-

sionwillaimatdefiningcorruption,andhighlightitscausesaswellasitsnegative

impact.

Session3:Practicingtransparency!GoodGovernanceinthehealthsector.Facilitator:Dr.HansHogerzeil,WHO,Switzerland

Panellists:

•Dr.MaureenLewis,WorldBank

•Mr.JimGee,KPMGForensic,UnitedKingdom

•Mr.PaulVincke,EuropeanHealthcareFraudandCorruptionNetwork(EHFCN),Belgium

•Dr.EricNoehrenberg,InternationalFederationofPharmaceuticalManufacturers&

Associations,Switzerland

Thepharmaceuticalsectorisanintegralelementofhealthsystems.Activitiesinmedi-

cinesregulationandsupplyhaveadirectimpactonhealthsystems'functioningand

viceversa.Effortstopromotegoodgovernanceinthepharmaceuticalsectorandinthe

healthsectorasawholeneedtocomplementeachother.Inthissession,panelistswill

shedadditionallightonhowhealthcaresystemscanbeprotectedfromabuse.

Session4:Keepingittogether!ThebasicingredientsforensuringGoodGovernance.Facilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup

Panellists:

•Dr.EloyAnello,NùrUniversity,Bolivia

•Dr.SonjaFüsser,MinistryofHealth,Germany

•Mrs.FatumaSichale,Anti-CorruptionCommission,Kenya

Good governance programmes require a combination of various, complementary

20

components.These include:anethical frameworkandcodeofconduct;established

anti-corruption legislation; regulationsandadministrativeprocedures;collaboration

mechanismsbetweenexistinganti-corruptioninitiatives;whistle-blowingmechanisms;

andsanctionsforreprehensibleacts.Panellistswillshareexperiencesinimplementing

someofthesecomponentsatthecountryandgloballevels.

Session5:Questioningtransparency.Ourpanellistsrespondtoyou!Facilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup

Inthissession,yourpanellistswillreplytoyourquestionsthatmayhaveremainedun-

answeredfromthepreviousplenarysessions,ornewonesraisedduringtheafternoon

workshopsandinformaldiscussionsamongparticipants.Pleasetaketimetowriteyour

questionsandplacethemintheboxprovided.

Session6:Rollingouttransparency.Whatisyourrole?Facilitator:Dr.CliveOndari,WHO,Switzerland

Panellists:

•Mr.AnthonyBoni,USAID,UnitedStatesofAmerica

•Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines

•Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand

•Dr.ZafarMirza,WHORegionalOfficefortheEasternMediterranean,Egypt

Stakeholders in thepharmaceutical sectoraremanyanddiverse. They includedrug

regulatoryauthoritiesandmedicinessupplymanagers,civilsocietyorganizationsand

academia,thepublicandtheprivatesectors,donorsandrecipientgovernments.Each

onehasaroleandeventuallytheiractionswillbringchanges.Wemayhavedifferent

roles,butweshouldaimtomakeactivitiescomplementary intheglobalefforts to

increaseaccesstoqualitymedicines.Inthissessionwewilldiscusstherolesofeach

stakeholderinrollingouttransparency,andacallforactionwillbemade.

22

WORKSHOPSESSIONS’OBJECTIVES

DAY1 MODERATORS BACKGROUNDANDOBJECTIVES

WORKSHOP1(aandb):

BRIDGINGTHERESEARCHGAP–what do we still needtoknow,andhowdowegoaboutit?

Workshop1.a:AbuBakarAbdulMajeed,UniversityofTechnologyMara,MalaysiaPaulVincke,EuropeanHealthcareFraudandCorruptionNetwork(EHFCN),Belgium

Workshop1.b:NiyadaKiatying-Angsulee,ChulalongkornUniversity,ThailandClive Ondari,WHOHeadquarters,Geneva

Corruptpracticesinthepharmaceuticalsector are being increasingly docu-mented. For example, Transparency In-ternational’s Global Corruption Report2006consolidatesalargeamountoftheexisting knowledge. Still, the scale ofthesepracticesandtheirimpact(healthandeconomic)isnotyetfullyknown.

The objective of this workshop is todefine the areas where more researchwill be needed in order to betterprevent corrupt practices and promotegoodgovernanceinthepharmaceuticalsector.

Attheendofeachday:Presentation/feedbackfromworkshops.Note:8minutespergroup

Each workshop has a PC for notesand to prepare the short PowerPointpresentation which will be the resultofthediscussions.Themoderatorswillpresentfeedbackfromtheirgroup.

WORKSHOP2(aandb):

MAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY-how?

Workshop2.a:ChanvitTharathep,MinistryofHealth,ThailandSriSuryawati,GadjahMadaUniversity,Indonesia

Workshop2.b:Eshetu Wondemagegnehu,WHOConsultant,EthiopiaSirinartVasanavathana,OfficeofFoodandDrugAdministration,Thailand

Theinternetisaremarkableanduniquetooltopromotetransparency.Moreandmore medicines regulatory agenciespost on their website the informationthatneeds tobepubliclyavailable,aswell as the details of procedures foradministrativeprocesses.

Theobjectiveofthisworkshopistolearnfromcountriesthathavecomprehensiveinternet services that aim to promotetransparency in the pharmaceuticalsector.

23


WORKSHOP3(aandb):

ESTABLISHINGANATIONALGGMTASKFORCE–whatarethechallengesahead?

Workshop3.a:RosminahMohd.Din,MinistryofHealth,MalaysiaNazaritaTacandong,WHORegionalOfficefortheWesternPacific,Philippines

Workshop3.b:CaroleBelisario,ProcurementWatch,Inc.,PhilippinesSocorro Escalante,WHO,Philippines

Governments must delegate the implementation of a Good GovernanceforMedicines programme to an appro-priate implementing agency or taskforce. If such an agency or task forcedoes not already exist, it needs to beestablishedwiththeappropriatehumanandfinancialresources.

The objective of this workshop is tolearnfromcountriesthathaverecentlysetupaGoodGovernanceforMedicinesimplementingagencyonhowbesttogoaboutit.


Each workshop has a PC for notesand to prepare the short PowerPointpresentationwhichwillbetheresultofthediscussions.Themoderatorswillthenpresentfeedbackfromtheirgroup.

WORKSHOP4(aandb):

JOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES–whatworks,whatdoesn’t?

Workshop4.a:EloyAnello,NúrUniversity,BoliviaWilfred Dodoli,WHO,Malawi

Workshop4.b:Maria Miralles,ManagementSciencesforHealth,USA.Moses Chisale,WHORegionalOfficeforAfrica,Gabon

Mostcountrieshavealreadyestablishednational anti-corruption agencies aspartoftheireffortstotacklecorruptionwithacross-sectoralperspective.Theseagenciescanprovidestrongsupporttonational Good Governance for Medicines programmes. It is useful to establishcollaboration mechanisms with them,notonlytogaintheirsupportbutalsotoavoidduplicationofefforts.

The objective of this workshop is toidentify types of existing nationalagencies that can help national GoodGovernance for Medicines programmesand to define the best approach forestablishingcollaborationmechanisms.

24


WORKSHOP5(aandb):

CANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?-howdowebringtransparencytothegreyzone?

Workshop5.a:SirinartVasanavathana,OfficeofFoodandDrugAdministration,ThailandWilliamMfuko,WHO,Cambodia Workshop5.b:MosesChisale,WHORegionalOfficeforAfrica,GabonNazaritaTacandong,WHORegionalOfficefortheWesternPacific,Philippines

Gift-giving in the working environment iscommonpracticeinmanysettings.Onthe one hand, it is a way of showingappreciation of collaboration betweenstaff or institutions. On the other,studiesbysocialscientistshaveprovedthat gift-giving also creates a sense of indebtedness and reciprocity, and caninfluencedecision-makingprocesses.

The objective of this workshop isto review the impact of gift-givingpractices, and reflect on how thesepracticescanbechangedovertime.



WORKSHOP6(aandb):

DEFININGINTEGRITY–howdoweraisethe standards and motivatepermanentchange?

Workshop6.a:ChanvitTharathep,MinistryofHealth,ThailandEloyAnello,NúrUniversity,Bolivia

Workshop6.b:AbuBakarAbdulMajeed,UniversityofTechnologyMara,MalaysiaClive Ondari,WHOHeadquarters,Geneva

Overcoming corruption in the pharma-ceutical sector requires a long-term strategy and the implementation ofgood governance. Experience hasshown that its impact will depend onthe coordinated application of twobasicstrategies,oneestablishinganti-corruption laws and regulation for thepractice of pharmacy, and the otherbuildinginstitutional integritythroughthe promotion of moral values andethicalpractices.

This workshop will focus on thesecond strategy: building institutionalintegrity.

25


WORKSHOP7(aandb):

WHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?- who are the players?-whatwillbetheimpactonpublichealth?

Workshop7.a:Eshetu Wondemagegnehu,WHOConsultant,EthiopiaNiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand

Workshop7.b:JimGee,KPMGForensic,UnitedKingdomCaroleBelisario,ProcurementWatch,Inc.,Philippines

Having a vision of what a country orthe whole world would look like with acorrupt-freepharmaceutical sector isessential to designing a national Good GovernanceforMedicinesprogramme.Italso helps in acquiring themotivationand the drive to address an issue that isoftenperceivedasataboosubjectortoodifficulttotackle.

The objective of this workshop is todevelopaclearvisionofacorrupt-freepharmaceuticalsectorandfindwaystocreatethemotivationamongkeyplayerstoactuponit.



WORKSHOP8(aandb):

SERVINGTRANSPARENCY!-HowcanWHObeofbetterservicewhen facilitating theGGMprogrammeimplementation?Giveyourideasandfeedback.

Workshop8.a:Maria Miralles,ManagementSciencesforHealth(Virginia,USA)BudionoSantoso,WHORegionalOfficefortheWesternPacific

Workshop8.b:TsetsegmaaSanjjav,HealthSciencesUniversityofMongolia ZafarMirza,WHORegionalOfficefortheEasternMediterranean,Egypt

Since WHO established the GoodGovernance for Medicines programmein2004,amodeloperatingprocessanda technicalpackage for countrieshavebeendeveloped.Still,WHOisawarethatithasembarkedonalearningprocess,and its policies and technical packagewillneedtobefurtherrefinedovertheyears.

The objective of this workshop is toreflect on WHO’s work to date in thisarea and make recommendations on how it can better support countriesin implementing national GGMprogrammes.

NETWORKINGEVENTS

29

Monday 3rd December, 19.00 - 21.00

Venue:MontienthipRoomattheMontienHotel

Weinviteyoutojoinusforawelcomereception.Thisistheperfectopportunityto

meeteveryoneparticipatinginthemeetingandanexcellentnetworkingopportunity

toexchangeideas,shareexperiencesanddiscusstheoutcomeoftheprofessionalpro-

grammeofthefirstday.

OFFSITEDINNER:GRANDCHAOPHRAYACRUISE

Tuesday 4th December,DeparturefromtheMontienHotel18.30.

WearedelightedtoinviteyouforacruisealongtheChaophrayariver,theprincipal

riverofThailand,whichisregardedasthebloodlineoftheThaipeople.MuchofThai

historycanbetracedalongitsbanks.OnbothsidesoftheChaophrayariver,atourist

canseemagnificenttemplesandarchitecturalbuildings,includingtheFirstPresby-

terianChurch,theRoyalThaiNavyDockyard,theThaiMaritimeNavigationCompany,

theOldCustomsHouse,WatPrayunwong,WatArun,theGrandPalace,WatRakhang

Kositaram,andtheRoyalBoatHouse.

Wewillenjoyawonderfulbuffetdinner,accompaniedbylivemusicinthelovely

atmosphereofthecityofBangkok.

AGENDA

Checkintime: 18:45pmatRiverCityPier#1(Siphraya/charoenkrungsoi30)

Cruisingtime: 19:00pmto21:00pm

WELCOME!

WELCOMECOCKTAIL

SPEAKERS

32

Name: Prof. Abu Bakar Abdul Majeed

Institution: FacultyofPharmacy,UniversitiTeknologiMARA(UiTM)

Country: Malaysia

AbuBakarAbdulMajeedobtainedhisBachelorofPharmacydegreefromAl-ZagazigUniver-

sity,Egypt,in1983,PhDinNeurophysiologyfromSheffieldUniversityin1988andMasters

inBusinessAdministration(MBA)fromUniversitiSainsMalaysiain1996.

In1997AbuBakarjoinedtheInstituteofIslamicUnderstandingMalaysia(IKIM)as

seniorFellowattheCentreforEconomics,SocialScienceandTechnology.Hewrotefort-

nightlyintheSaturdayForumcolumnoftheNewStraitsTimesbetween1997-2002.In

2002AbuBakarwasawardedtwofellowships,onetodoresearchon ‘Bioethics’atthe

CentreforEuropeanIntegration(ZEI)inBonn,Germany,andtheotheranindividualin-

ternationalvisitor’sprogrammeon‘ReligionandSociety’bytheUSStateDepartmentin

September–October.

InFebruary2002AbuBakarwasappointedasProfessor,FacultyofPharmacy,Universiti

TeknologiMARA(UiTM),ShahAlam,andon1.9.2002asDeanoftheFaculty,UiTM,In

January2004,hewasmade FoundingChairmanof Collegeof Science and Technology,

comprising12science-basedfacultiesatUiTM,includingmedical,engineeringandapplied

sciences.

Hehaswrittenthebookentitled,‘MakingtheBestofBothWorlds–volume1:Faith

andScience’and‘MakingtheBestofBothWorlds–volume2:HeavenandEarth.’Among

thetitleseditedare:‘IslamandDevelopmentinAsia’,IslamicWorldandEurope–Some

Issues’,‘Bioethics–EthicsintheBiotechnologyCentury’,‘TheConceptandOperationsof

IslamicMedicine’,‘IslamandPreventiveMedicine’,‘IslamandMultimedia’,‘Enhancingthe

UnderstandingofIslamfortheMedia’,and‘NewKnowledge–R&DintheIslamicWorld.’

AbuBakarismarriedtoBalkhisOthman.Theyhavetwoboys,AbdulAzeemandAbdul

Azeez,andtwingirls,AisyahandAtikah.Inhisleisuretime,AbuBakarenjoystravelling,

sportsandphotography.

33

Name: Mrs. Gergana Andre

Institution: InternationalHealthcareandHealthInsuranceInstitute

Country: Bulgaria

Mrs.GerganaAndrehasaMastersdegreeinPharmacyandherpostgraduatespecial-

izationisonManagementSystemsofWholesalersandRetailPharmacies.Later,she

obtainedaMastersdegreeinHealthManagement.Currentlysheisdoingadoctorate

on“TheNationalDrugPolicyModelasaMovingFactorinHealthReforminBulgaria”.

From1995sheworkedfortheinternationalhumanitarianorganization“Pharmaciens

SansFrontières”inTajikistan,BulgariaandEgyptandlatershemovedtotheBulgarian

stateadministration.From2000to2002Mrs.Andreledthe“DrugPolicy”Department

attheMinistryofHealthinBulgariawhereshewasresponsibleforharmonizingphar-

maceuticalsectorlegislationwithEUstandards.

At presentMrs.Andre isHeadof the ”PharmaceuticalAnalysis andDrugPolicy”

department.Sheworksontheintegrationofinformationinthepharmaceuticalsec-

tor,andorganizationandparticipationininternationalprojectsinthepharmaceutical

sector, including projects under Phare Programmes, DG SANCO, participation in the

StudyofGovernanceinBulgaria’sPharmaceuticalSystembytheIRISCenter,andthe

UniversityofMaryland,USA.

34

Name: Dr. Eloy Anello

Institution: AndeanCentreofExcellenceforTraining,NurUniversity

Country: Bolivia

Dr.EloyAnelloistheNationalDirectorofNurUniversity’s“AndeanCenterofExcellence

forTraining” inSantaCruz,Bolivia. HeisalsotheGeneralAcademicandResearch

AdvisorforNurUniversity.Duringthelast25yearshehasprovidedconsultancyand

trainingservices in theareasofpublichealthandeducationtomany international

agenciesthroughoutLatinAmerica.These includePAHO/WorldHealthOrganization,

UNICEF, World Bank, Inter-American Development Bank, Kellogg Foundation, Ford

Foundation,USAID,DFID,andPlanInternational.Forthelasttwoyearshehasbeena

consultanttoWHO’sGoodGovernanceforMedicinesprogramme,developinganethical

frameworkforgoodgovernanceinthepharmaceuticalpublicsector.

35

Name: Dr. Niyada Kiatying-Angsulee

Institution: FacultyofPharmaceuticalSciences,ChulalongkornUniversity

Country: Thailand

Niyada Kiatying-Angsulee has a BSc in Pharmacy from Chulalongkorn University in

Thailand,anMSc inPharmacology fromMahidolUniversity,Thailand,andaPhD in

HealthPolicyfromtheLondonSchoolofHygieneandTropicalMedicines,University

ofLondon,UK.

Herareasofexpertiseincludedrugsystems,consumerprotection,regulation,policy

analysis,women’sdrugs,ethicsandpromotion.Sheisinvolvedinseveralnationaland

internationalacademicactivities,suchas:

• AdvisorfortheWorldHealthOrganization

• GoverningCouncilMemberofHealthActionInternationalAsiaPacific

• ExpertMemberoftheDrugCommitteeaccordingtotheDrugActB.E.2510

• MemberoftheSubcommitteeonSafetyofMedicines,underthe

DrugCommittee.

• Reviewer,ThaiHealthPromotionFund

• MemberofAdministrativeBoard,MScandPhD.SocialandAdministrative

(InternationalProgram)

• MemberoftheAdministrativeBoard,CenterforPeaceandConflictStudies,

ChulalongkornUniversity

• Chair,SocialPharmacyResearchUnit,ChulalongkornUniversity

36

Name: Dr. Guitelle Baghdadi-Sabeti

Institution: WorldHealthOrganization

Country: Switzerland

GuitelleBaghdadi-Sabetihasover15yearsexperienceinpublichealthanddevelop-

mentwork,particularlyininternationalpharmaceuticalpoliciesandpracticesaimedat

increasingaccesstogoodqualityessentialmedicines.Shehascollaboratedandprovid-

edcountrysupporttoover50MinistriesofHealth,NGOsanddevelopmentpartners.

SheholdsaMastersdegreeandaDoctorate inPharmacy from theUniversityof

GrenobleaswellasaMastersinPublicHealthfromtheUniversitéLibredeBruxelles.

Shestartedhercareerin1991inRomaniaworkingwithPharmaciensSansFrontières

andjoinedWHOin1994whereshehasworkedindifferentlocationsandcapacities.

These include theWHOofficeat theUnitedNations inNewYork, theWHOcountry

officeinHaitiandsince1998shehasworkedatWHOHeadquarters,Geneva,inthe

DepartmentofMedicinesPolicy.

InNovember2004,sheinitiatedanddevelopedWHO’sGoodGovernanceforMedi-

cinesprogramme,aimedatpromotinggoodgovernanceandcurbingcorruptioninthe

pharmaceuticalsector.Thisprojectiscurrentlyoperatingin19countriesandisusing

abottom-upapproach,involvingcountryofficialsandinternationalexpertsinthede-

velopmentofnationalgoodgovernanceprogrammesforthepharmaceuticalsector.

37

Name: Mrs. Carole Belisario

Institution: ProcurementWatch,Inc.

Country: Philippines

Ms.CarolineR.BelisarioobtainedherAccountancyDegreeattheHealdBusinessCol-

legeinSanFrancisco,CaliforniaU.S.A.ShehasbeenworkingatProcurementWatch,

IncorporatedinthecapacityasSupervisingTechnicalOfficersince2001andafree-

lanceGovernance/ProcurementConsultant.

Some of her involvement in the area of Governance include Good Governance for

MedicinesProgrammeoftheWorldHealthOrganization,ProcurementAssessmentof

sixteen(16)LocalGovernmentUnitsfortheHealthSectorPolicySupportProgramme

oftheEuropeanUnionCommission,DifferentialExpenditureandEfficiencyMeasure-

mentToolforTAF-USAID,andpromotinggreatertransparencyandaccountability in

thehealthsectorthroughtheMedicinesTransparencyAlliance(MeTA)Council.

38

Name: Mr. Anthony Boni

Institution: UnitedStatesAgencyforInternationalDevelopment(USAID)

Country: UnitedStatesofAmerica

AnthonyBoniisaPharmaceuticalManagementSpecialistintheOfficeofHealth,Infec-

tiousDiseasesandNutritionoftheGlobalHealthBureauoftheU.S.AgencyforInter-

nationalDevelopment(USAID).HehasdesignedandmanagestheAgency’sworldwide

technicalassistanceprogrammesinpharmaceuticalmanagement,druginformationand

medicinesqualityassurance. Hisnewprogramme,StrengtheningPharmaceuticalSys-

tems,hasimprovinggovernanceinthepharmaceuticalsectorasamajorobjective.

Mr.Boni has direct involvement in the implementationofHIV/AIDS,malaria, TB,

maternalandchildhealth,andantimicrobialresistance(AMR)programmesinmorethan

30countries,andhascollaboratedwithallinternationalorganizationsandinitiatives

workinginthepharmaceuticalarea.HealsoconsultedwiththeGlobalFundtoFight

AIDS,MalariaandTuberculosis(GF)regardingqualityassuranceissues,workedwiththe

procurementteamonsupplychainassessmentmethodologies,andmanagesUSAIDtech-

nicalassistancetoGFrecipientstoremovebottlenecksimpedingtheimplementationof

countryprogrammes.

AtechnicaladvisortotheU.S.Government,heprovidesguidanceonpharmaceutical

managementandprocurement,qualityassuranceandprequalificationissues,accessto

andtherationaluseofmedicines,IPRandpatents,andAMR.Withregardtothelatter,

hedraftedtheAMRcomponentofUSAID’sInfectiousDiseaseStrategyandisresponsible

forUSAID’sportfolioofAMRactivities.InhisAMRrole,heprovidedtechnicalandfi-

nancialsupporttotheWorldHealthOrganizationforthedevelopmentoftheWHOGlobal

StrategyfortheContainmentofAntimicrobialResistance.Heisalsoamemberofvarious

internationaltaskforces,includingtheGlobalFund/UNITAIDTechnicalAdvisoryGroup

andtheUnitedStatesPharmacopeiaInternationalHealthExpertCommittee.

PriortojoiningtheHealthOffice,hehelpedsetuptheAgency’scentralizedprocure-

mentanddistributionsystemsforcontraceptivecommoditiesandmanagedtheprovision

oftechnicalassistanceinlogisticsmanagementtoUSAID-supportedprogrammes.

39

Name: Dr. Socorro Escalante

Institution: WorldHealthOrganizationRegionalOfficefortheWesternPacific


DrSocorroZarateEscalanteiscurrentlytheProgrammeOfficerforPharmaceuticalsat

theWorldHealthOrganizationOffice inthePhilippines.Sheisamedicaldoctorby

profession,hasalawdegreeandaMastersinBusinessAdministrationinHealthfrom

theAteneoGraduateSchoolofBusiness(AteneodeManilaUniversity).

DrEscalantewasanelectedmemberoftheProvincialBoardofLaUnionfornine

years,andassuchchairedtheCommitteesonHealth,EthicsandGoodGovernmentand

SocialWelfareandDevelopment.Shehasextensiveexperienceoflocalgovernance,lo-

calhealthsystemsandpharmaceuticalmanagementatthelocallevel.Priortojoining

WHO,shealsoworkedwiththeCentreforHealthDevelopment-IoftheDepartmentof

Health.

40

Name: Dr. Sonja Füsser

Institution: FederalMinistryofHealth,Bonn,Germany

Country: Germany

SonjagraduatedfromCologneUniversitywithadegreeinlaw.SheholdsaPhDinlaw

andisaspecialistinthefieldofsocialsecurityandhealthsystem.

Sonja started her career with the German Federal (Social) Insurance Authority

(Bundesversicherungsamt)where shedealtwith legal problemswhicharise in con-

nectionwiththeauthorizationproceduresoftheDiseaseManagementPrograms.In

2005SonjajoinedtheGermanFederalMinistryofHealthasdeskofficer(Referentin)

anddeputydirector.HerareaofresponsibilityisthesupervisionoftheFederalSelf-

GovernmentBodies,theimplementationofanewreformlegislationandtheregulation

ofpharmaceuticalspendinginthestatutoryhealthinsurancesystem.FromSeptember

2005toMarch2006SonjaworkedfortheEuropeanCommission,Directorate-General

HealthandConsumerProtection.

41

Name: Mr. Jim Gee

Institution: KPMGForensic

Country: UnitedKingdom

Jim Gee hasmore than 25 years operational, policy and strategic experience as a

counterfraudspecialistoperatingintheUKincentralgovernment,localgovernment

andtheNHS.

After8yearsheadingupcounterfraudworkinLondonlocalauthoritiesandadvising

theAssociationofLondonGovernment,hejoinedtheDepartmentofHealthin1998

asDirectorofCounterFraudServices,toadvisetheMinisterofStateforHealthandto

establishandheadthenewNHSCounterFraudService(NHSCFS).In2003hebecame

ChiefExecutiveOfficeroftheNHSCounterFraudandSecurityManagementService.

Between2000and2006theNHSCFShasfinanciallybenefitedtheNHStothetune

ofaround£811million–a12:1returngeneratedfroma£67millionbudget.Fraud

losseswerereducedbyupto60%.TheNHSCFSalsohasa96%successfulprosecution

rateandhasneverlostacivillegalcaseonfraud.In2003hisremitwasexpanded

tocoversecuritymanagementintheNHSandtoensuretheproperprotectionofNHS

staff,patients,resourcesandproperty.Sincethattimehehassucceededinreducing

assaultsagainststaffforthefirsttime.

In 2005 he became Director-General of the new EuropeanHealthcare Fraud and

CorruptionNetwork(EHFCN),anorganizationwhichhehelpedfoundin2004.Atthe

foundingconference,organizationsfrom29countriesunanimouslyagreedtheEuro-

peanHealthcareFraudandCorruptionDeclaration.

Since2005,JimhasbeenamemberoftheUKGovernment’sFraudReviewSteering

GroupwhichdevelopedtheUK’sfirstcross-economycounterfraudstrategy.Thisisnow

beingimplementedbyGovernmentandtheUKAttorney-Generalaskedhimtochairthe

FraudReview’sStakeholderGroupandWorkingGrouponFraudLossMeasurement.

Atthestartof2007,hejoinedKPMGForensicasitsDirectorofFraudServices,with

aremittodeveloptheholistic,professionalapproachhepioneeredintheNHS,and

toofferahigh-quality,integratedservicedesignedtoaccuratelyidentifyandreduce

fraudlosses.HehassincedeliveredthisservicetotheNewZealandMinistryofHealth

andiscurrentlyindiscussionswithcolleagueinCanadaandSouthAfrica.

42

Name: Dr. Hans V. Hogerzeil



HansV.HogerzeilMD,PhD,DSc,FRCPEdin.qualifiedasamedicaldoctorfromLeiden

UniversityintheNetherlandsandreceivedaPhDinpublichealthin1984.Forfive

yearshewasamissiondoctorinIndiaandGhanaandin1985hejoinedtheWHOAc-

tionProgrammeonEssentialDrugs,firstintheRegionalOfficefortheEasternMediter-

raneaninAlexandria,andlaterinWHO’sHeadquartersinGeneva.Asastaffmemberof

WHOhehasadvisedmorethan40developingcountries,especiallyinAfricaandAsia,

onthedevelopmentoftheirnationalmedicinespolicy,essentialdrugslistandessen-

tialdrugsprogramme.AsSecretaryoftheWHOExpertCommitteeontheSelectionand

UseofEssentialMedicinesheinitiatedtherecentchangesinproceduresforupdating

theModelListofEssentialMedicines,withstrongeremphasisonevidence-basedselec-

tions.Heestablishedtheweb-basedWHOEssentialMedicinesLibraryandisoneofthe

editorsoftheWHOModelFormulary2006.

InhispositionasDirectoroftheDepartmentofMedicinesPolicyandStandardshe

istechnicallyresponsibleforallWHO’sglobalpolicies,normsandstandardsonmedi-

cines.HeisalsotheChairoftheInteragencyPharmaceuticalCoordinationGroupwhich

coordinatesthepharmaceuticalpoliciesandprogrammesofallmajorUNagencies,the

GlobalFundandtheWorldBank.

DrHogerzeilistheeditorofseveralWHObooksonessentialmedicinespolicies,the

qualityuseofmedicines,medicinesinemergencysituationsandessentialmedicines

forreproductivehealth.Hehaspublishedover50scientificpapersinpeer-reviewed

journalsandteacheseveryyearatinternationalcoursesallovertheworld.In1996he

wasinvitedtobecomeaFellowoftheRoyalCollegeofPhysiciansinEdinburghandin

1998hereceivedanhonoraryDoctorateofSciencefromtheRobertGordonUniversity

inAberdeen,Scotland.Heismarriedwithfourchildren.

Hisrecentinterestsincludeessentialmedicinesforreproductivehealth,andaccess

toessentialmedicinesaspartofthefulfilmentoftherighttohealth.

43

Name: Mr. Martin Kreutner

Institution: FederalBureauforInternalAffairs,FederalMinistryoftheInterior

Country: Austria

Bornin1964;studiedlawattheUniversityofInnsbruck.Commissionedofficerinthe

AustrianArmedForceswithvarioustroop,staffandministerialassignments;serveda

totaloffiveyearswithdifferentUNandNATOmissionsinSyria,Israel,Lebanonand

Albania.In2000,hetransferredtotheAustrianFederalMinistryoftheInteriorand

wascommissionedtobuildupananti-corruptionserviceunit(BIA);since2001heads

theAustrianFederalBureauforInternalAffairs(BIA);2004obtainedanadditional

degreeasMasterofScienceinPolicingandPublicOrderStudiesattheUniversityof

LeicesterinU.K.;guest-lecturedoninternationalhumanitarianlawattheGermanRed

Cross,aswellastheRuhrUniversityinBochum,Germany;healsolecturedongeneral

andspecialsecurityandanti-corruptiontopicsatseveralEuropeansecurityandmili-

taryacademiesaswellasuniversities.Inthecourseofhisworkhehasspokenwidely

atinternationalconferences–interalia–inBrazil,Canada,China,HongKong,Jordan,

ThailandandthroughoutEurope.

MemberofInterpol’sInternationalGroupofExpertsonCorruption,memberofthe

ExecutiveCommitteeoftheEuropeanHealthcareFraudandCorruptionNetwork,EH-

FCN,memberoftheAdvisoryBoardtoTransparencyInternational–ChapterAustria,

jurortotheSpeyererQualityCompetitiononCorruption,wasputinchargeofcorrup-

tionissuesbytheWorldBank;heisacourtexpertongeneralcriminologyaswellas

VIPprotection,inadditiontobeingchairmanoftheSupremeDisciplinaryCommission

oftheFederalMinistryoftheInteriorandmemberoftheFederalAppealsTribunal;

authorofmanyarticlesandpapersonsecurityissues,editorofabookoncorruption

(2006)andco-authorofalegalcommentary(2005).

MartinKreutnerhasmaintainedarelationshipwithhispartner,apharmacist.He

lovessports,musicandnature.

44

Name: Dr. Kerstin Leitner

Institution: WorldHealthOrganizationGGMGlobalAdvisoryGroup

Country: Germany

KerstinLeitnerearnedherPhDwithathesisonsocio-economicdevelopmentinKenya

atBerlin’sFreeUniversityinhernativeGermanyin1975.Ayearlatersheembarked

onwhatwastobecomea27yearcareerwiththeUNDevelopmentProgramme(UNDP).

SheheldseveralpostsinAfrica,Asia,EuropeandtheMiddleEast.Mostrecently,from

1998until2003,shewasUNResidentCoordinatorandUNDPResidentRepresentative

inChina.Beforethat,from1997–1998,shewasSeniorSpecialAdvisertotheUNDP

AssistantAdministratorandDirectorinAsiaandthePacific.

InSeptember2003,shebecameAssistantDirector-GeneralofWHO’sSustainableDe-

velopmentandHealthyEnvironmentsClusterofdepartments.Herteamhassharpened

itsfocusonprovidinginformationandknowledgetonumerousWHOMemberStateson

thepublichealthimpactofenvironmentalfactors.

45

Name: Dr. Maureen Lewis

Institution: TheWorldBank


Maureen Lewis is Chief Economist,HumanDevelopment at theWorld Bank encom-

passinghealth,educationandsocialprotection.Muchofherresearch,publications

andpolicyworkexaminegovernanceandefficiencyinthesocialsectors,particularly

health. ShewasformerlyaSeniorFellowattheCenter forGlobalDevelopmentfor

twoyearsandpriortothatmanagedaunitintheWorldBankdedicatedtoeconomic

policyandhumandevelopmentresearchandprogramsinEasternEuropeandCentral

Asia.BeforejoiningtheWorldBank,sheestablishedandoversawtheinternational

healthpolicyagendaatTheUrbanInstitute.Shehaspublisheddozensofarticlesin

peer-reviewedjournalsonarangeoftopicsinthesocialsectors.SheearnedherPhD.

atJohnsHopkinsUniversity.

46

Name: Mr. Changyuan Lin

Institution: StateFoodandDrugAdministration

Country: People’sRepublicofChina

Mr.ChangyuanLinisaprincipalstaffmemberoftheGeneralOfficeintheStateFood

andDrugAdministration(SFDA),PRC,whereheisresponsiblefordraftingpolicyre-

portsandspeechesthatneedtobedeliveredbytheCommissioner.BeforeJoiningthe

SFDAin2004,hehadbeenaresearcherandassistantprofessorfor4yearsintheLaw

Institute,oftheChineseAcademyofSocialSciences.Alawyer,Mr.ChangyuanLinhas

bothbachelorandmastersdegreesinlawandwasawardedapostgraduatediploma

withdistinctionbyLondonUniversityin2003.

47

Name: Dr. Maria Miralles

Institution: ManagementSciencesforHealth’sRational

PharmaceuticalManagement(MSH)


Dr.MariaMirallesistheDeputyDirectorforManagementSciencesforHealth’sRatio-

nalPharmaceuticalManagement(RPM)PlusProgramaswellastherecentlyawarded

StrengtheningPharmaceuticalSystems(SPS)ProgramandisbasedinArlington,Vir-

ginia.Shehasmorethan25yearsofexperience inpublichealthand international

development,halfofthemwithafocusonpharmaceuticalmanagement.Withastrong

backgroundinoperationsresearch,researchdesignandmethodology,andmonitoring

andevaluation,shehasworkedinallaspectsofpharmaceuticalsystemsandsupply

management.WithRPMPlusandSPS,Dr.Mirallesoverseesprogrammesinmorethan

20countries.Sheguidesthedevelopmentandimplementationofappropriatephar-

maceuticalmanagementmechanisms and systems based on best practices and the

principlesofgoodgovernancetoincreaseaccesstoqualityessentialmedicinesand

enhancetheeffectivenessofhealthcaresystems.SheholdsaPhDinPharmacyHealth

CareAdministrationinadditiontoaMastersdegreeinAnthropology.

48

Name: Dr. Zafar Ullah Mirza


RegionalOfficefortheEasternMediterranean

Country: Egypt

CurrentlyworkingasRegionalAdviser–EssentialMedicines&BiologicalsattheEast-

ernMediterraneanRegionalOfficeoftheWorldHealthOrganizationinCairo,Egypt,

covering22countries.MedicalgraduatewithMastersinPublicHealth.Specialinter-

est, experience and trainings in drug policy/management issues. Other experience

includespsychiatryandruralhealthservice.In1992establishedanon-profit“Associa-

tionforRationalUseofMedicationinPakistan”latertransformeditintothefirstna-

tionalconsumerorganizationinthecountry:“TheNetworkforConsumerProtection”,

servedasitsfoundingExecutiveDirectorfor12years.Theorganizationisactivein

pharmaceuticals, tobacco,water, unethicalmarketing, consumermobilization, legal

research,consumerredress,tradeissuesrelevanttopublichealth.In1995wonBri-

tanniaScholarshipforMPHinLondonandselectedasEisenhowerFellowfortheyear

2003byEisenhowerFoundation,USA.HasservedonthefacultyofBostonSchoolof

PublicHealthandwaspartofUNMillenniumprojectTaskForce.Servedasmemberof

FoundationBoardofHealthActionInternationalandasmemberofWHOInternational

ScientificAdvisoryGrouponGlobalizationandHealth.LedadelegationofConsumers

International at the 3rd& 4thWTOministerialmeetings in Seattle and Doha. Co-

authoredajointWTO/WHOpublication:“WTOAgreementsandPublicHealth”.

49

Name: Mrs. Rosminah Mohd. Din

Institution: PharmaceuticalServicesDivision,MinistryofHealth

Country: Malaysia

RosminahMohd.DinhasaMastersinMedicalScience(PublicHealth),2003,University

ofMalaya,Malaysia,aswellasaBachelorofPharmacy,1983,SouthAustralianInsti-

tuteofTechnology,Australia.

SheistodayHeadoftheMinistryofHealthDrugFormularyUnit,inthePharmaceu-

ticalServicesDivision.HermainjobfunctionsincludeManagementoftheMOHdrug

formulary,developmentoftheMalaysiandrugcode(MDC),managementofrequestsfor

drugsnotincludedintheMOHformulary,andSecretariattotheNationalDrugFormu-

laryPanel,whichisresponsiblefortheselectionofdrugsforinclusionintheMOHdrug

formulary,NationalEssentialDrugsList(NEDL),pharmacoeconomicsandGGM.

Herareasofinterestsare:drugutilisation,qualityuseofmedicines,pharmacoeco-

nomics,medicationsafetyandgoodgovernance.

50

Name: Ms. Nazarita Tacandong

Institution: WorldHealthOrganizationRegionalOfficefortheWesternPacific


Ms.Tacandongisapharmacistbyprofession.ShehasobtainedherBachelorofScience

inPharmacyattheSouthwesternUniversity,CebuCity,Philippines.Shepursuedher

studiesandgraduatedwithaMastersinPublicAdministration.MsTacandongisashort

termprofessionalattheWorldHealthOrganization,WesternPacificRegionalOfficein

Manila.

She has beenwith the Bureau of Food and Drugs, the national drug regulatory

authorityofthePhilippines,for29years.Shehastakentheleadinthefightagainst

counterfeitdrugsinthecountry.Assuch,shehasbeeninvitedasresourcespeaker/

lecturertomanyconferences,bothlocalandinternational.

ShewasresponsiblefortheimplementationofGoodManufacturingPractices(GMP)

forpharmaceuticalestablishmentsandlaterforcosmeticestablishments,andeventu-

allyforthedraftingofGMPguidelinesforfoodestablishments.

Ms.TacandonghasrecentlyreceivedtheAWARDOFEXCELLENCEfromthePhilippine

FederationofProfessionalAssociationsofthePhilippines.InJunethisyear,shewas

awarded“THEPRCOUTSTANDINGPROFESSIONALOFTHEYEAR”inthefieldofPharmacy

andawardedasALUMNIGREATinJanuaryandalsoasOutstandingPharmacistinthe

Governmentin2006.

Ms.TacandonghasbeeninstrumentalinthedevelopmentoftheNationalEthical

InfrastructureforGoodGovernanceinthePhilippines.ShehasrepresentedtheBureau

andthecountryinmeetingsongoodgovernance.

51

Name: Dr. Eric Noehrenberg

Institution: InternationalFederationofPharmaceuticalManufacturers

&Associations(IFPMA)


Dr.EricNoehrenbergisDirectorofInternationalTradeandMarketIssuesattheIn-

ternationalFederationofPharmaceuticalManufacturers&Associationsandhasheld

thispositionsinceOctober1999.Inthiscapacity,Dr.Noehrenbergisresponsiblefor

negotiations regarding trade andmarket issuesbetween theglobal, research-based

pharmaceuticalindustryandthemajorinternationalorganizationsinvolvedinthese

issues, including the, theWorldHealthOrganization (WHO), theWorld TradeOrga-

nization(WTO),andtheWorldIntellectualPropertyOrganization(WIPO).Heisalso

responsibleforAIDSissues,bioterrorismconcerns,andInternetmatters.

Prior to joiningIFPMA,Dr.NoehrenbergwasanExternalRelationsOfficer in the

unitofDonorandCorporateRelations,JointUnitedNationsProgrammeonHIV/AIDS

(UNAIDS),from1996toOctober1999.Dr.NoehrenbergwasaProjectManageratthe

WorldEconomicForumfrom1994to1996,wherehewasresponsibleforthedevelop-

mentoftheGlobalGrowthCompaniesmembership,aswellasforcoordinatingForum

eventsinSingapore,theMekongSubregionandChicago.

Dr.Noehrenbergbeganhiscareerinthehealthfieldasapolicyanalystinthede-

partmentofPharmaEconomicsandPolicyatCIBA-GEIGY(nowNovartis)headquarters

inBasel.

Dr.Noehrenberggraduatedwithadoctoratecum laudefromtheUniversityofTübin-

gen,Germany.Heearnedhismaster’sdegreewitha concentration in International

TradeandFinance fromHarvardUniversityandhisBachelorofArts fromPrinceton

University.

52

Name: Dr. Clive Ondari



CliveOndarihasover20yearsofexperienceinpharmaceuticalpoliciesandprogrammes,

havingworkedfortheGovernmentofKenyaandWHOonvariousassignments.Heholds

aDoctorateinPharmaceuticalSciencesandMasterofScienceinBusinessAdministra-

tion(StrategicPlanning).Hestartedhiscareerinacademiaandregulatoryaffairsin

KenyawherehewasAssociateProfessorandHeadofDepartmentattheUniversityof

NairobiandChairmanofthePharmacyBoard(CommitteeonRegistrationofMedicines)

forover10years.

Forthelast2years,hehasbeentheCoordinatorforMedicinesPolicy,Accessand

RationalUse,whichincorporatesWHOHeadquarter’sguidanceworkonnationalmedi-

cinespolicies,selection,suppliesmanagementandrationaluseofmedicines.

53

Name: Dr. Steven Rood

Institution: TheAsiaFoundation


StevenRoodisTheAsiaFoundation’scountryrepresentativeforthePhilippinesand

PacificIslandNations.InhisconcurrentroleasRegionalAdvisorforLocalGovernance,

hehelpstobuildlocalgovernment,decentralization,andmunicipalgovernmentpro-

grammesthroughouttheregion.Dr.Rood,anexpertonlocalgovernment,decentral-

ization,andpublicopinionpolling,hasbeenaconsultanttobothgovernmentand

nongovernmentalorganizations,includingAssociatesinRuralDevelopmentInc.,The

SocialWeatherStationsinManila,andUSAID.Dr.RoodservedasprofessorofPolitical

ScienceattheUniversityofthePhilippinesCollegeBaguiofrom1981until joining

theFoundationin1999,andwastheonlyforeignfacultymemberwithtenureinthe

UniversityofthePhilippinessystem.

Dr.RoodistheauthorofanumberofworksonFilipinopolitics,withaspecialfocus

ondemocracyanddecentralization.HismostrecentpublicationisForging Sustainable

Peace in Mindanao: The Role of Civil Society(East-WestCenterWashington,PolicyStud-

ies17,2005);

Education:B.A. inpoliticalscience,UniversityofWashington;M.A.andPh.D. in

politicalsciencefromBostonUniversity.

54

Name: Dr. Tsetsegmaa Sanjjav

Institution: HealthSciences,UniversityofMongolia

Country: Mongolia

ProfessorSanjayhasaPh.Dinpharmacy.SheisalsoDeanoftheSchoolofPharmacy,

HealthSciencesattheUniversityofMongoliainUlaanbaatar.

55

Name: Mrs. Fatuma Sichale

Institution: KenyaAnti-CorruptionCommission(KACC)

Country: Kenya

Mrs.FatumaSichaleistheDeputyDirector/AssistantDirectorin-chargeoftheLegal

ServicesDirectorateattheKenyaAnti-CorruptionCommission.TheKenyaAnti-Corrup-

tionCommissionisastatutorybodysetuptospearheadthefightagainstcorruption

inKenya.ShewasappointedtothispositioninSeptember2004.

Prior toherappointmentasanAssistantDirector,Mrs.Sichalewas inprivate legal

practice.Herpracticeofthelawspansaperiodofover20years.Shehadalsohada

shortstintatthejudiciarywheresheresignedatthelevelofResidentMagistrateto

enterintothecompetitiveworldoflegalpractice.

Besidesworking in the judiciaryandher legalpractice,Mrs. FatumaSichalehas

servedinothercapacitiesi.e.

i) ShewasoneofthesevenBoardMembersofthedefunctKenya

Anti-CorruptionAuthority.

ii) AdvisortotheKenyaAnti-CorruptionPoliceUnit,abodythatreplacedthe

defunctKACA.

iii) CouncilMember,LawSocietyofKenya.

iv) CouncilMemberoftheFederationofWomenLawyers(FIDA)KenyaChapter.

v) BoardMember,KenyaAnti-CorruptionCommissionbeforeresigningto

competitivelyapplyforthepositionofanAssistantDirector,LegalServices.

Mrs.SichaleholdsaBachelorofLawdegreefromtheUniversityofNairobiandaDi-

plomainLawandPracticefromtheKenyaSchoolofLaw.Sheisanadvocateofthe

HighCourtofKenya.

56

Name: Dr. Sri Suryawati (Surya)

Institution: CentreforClinicalPharmacologyandMedicinesPolicyStudies,

GadjahMadaUniversity

Country: Indonesia

Dr.SriSuryawati(Surya)isActingDirectoroftheCentreforClinicalPharmacologyand

MedicinesPolicyStudies,andCoordinatoroftheMasterDegreeProgramforMedicine

PolicyandManagement,GadjahMadaUniversity.

SheisamemberoftheUNInternationalNarcoticsControlBoard.ExecutiveBoard

oftheInternationalNetworkforRationalUseofDrugs(INRUD),andtheWHOExpert

AdvisoryPanelforMedicinePolicyandManagement.SheisalsoaWHOExpertCommit-

teememberfortheSelectionandUseofEssentialMedicines(since2002),WHOExpert

CommitteememberfortheMedicinesCausingDependency(2002-2005),andamember

oftheUNMillenniumProject:MillenniumDevelopmentGoalTaskForce5onHIV/AIDS,

TB,Malaria,andAccesstoEssentialMedicines.

Herareasofworkincludemedicinespolicyandpromotingthequalityuseofmedi-

cines(since1990),drugevaluationandnewdrugapplication(since1987),andclini-

cal pharmacokinetics and bioequivalence testing (since 1984). Since 1996 she has

supervised>100master anddoctoral thesesonclinicalpharmacokinetics,medicine

policy,medicinesupplymanagement,andimprovingmedicineuseinhealthfacilities

andthecommunity.

Shealsoworksasaninternationalconsultantonessentialmedicineprogrammes,

promotingrationaluseofmedicines,medicinepolicy,drugevaluation,bioequivalence

testing,aswellasbeingaFacilitatoronvariousinternationaltrainingcourses,e.g.

onPromotingRationalUseofMedicines,HospitalDrugandTherapeuticsCommittees,

andMedicinePolicyIssuesinDevelopingCountries.

57

Name: Dr. Chanvit Tharathep

Institution: BureauofHealthServiceSystemDevelopment,

HealthServiceSupportDepartment,

MinistryofPublicHealth.

Country: Thailand

Dr.MD.ChanvitTharathep,FRCST(FellowoftheRoyalCollegeofSurgeonsThailand),

Diploma of FamilyMedicine Thailand, is the Director of theHealth Service System

DevelopmentBureauinThailand.

Other experiences: system analysis, hospital information systems, diagnostic-

relatedgroupresearchawards:

1. Peritoneovenousshuntforascites;Preliminaryreport.

2. ComputerbasedinformationsystemforORregister.

3. Re-engineeringoftheOutPatientDepartment.

4. Peritoneovenousshuntforascitesormedicaltreatment,aprospective

comparativestudy.

CurrentResponsibilities:

• ProjectaboutautonomoushospitalsinThailand.

• Implementationofdiagnostic-relatedgroup(DRG).

• HospitalinformationsystemandotherinformationintheProvincial

HospitalDivision.

• Financingandbudgetingforhospitals.

• PharmacyInformationCentre.

58

Name: Dr. Sirinart Vasanavathana

Institution: OfficeofFoodandDrugAdministration,

MinistryofPublicHealth

Country: Thailand

Education:

B.Sc.inPharmaceuticalSciencefromFacultyofPharmacy,Mahidol

University,Bangkok,Thailand

M.S.andPh.DinMedicinalChemistry,CollegeofPharmacy,TheOhioState

University,Columbus,Ohio,U.S.A.

Experience:

Reviewquality,efficacyandsafetyofpharmaceuticalproductssubmittedforregistra-

tioninThailand.ReviewethicalandscientificissuesfortheEthicsCommitteeofthe

MinistryofPublicHealth,Thailand.Co-developmentofguidelinesonbioequivalence

studies,GCPinThailandandWHOGMPforRadiopharmaceuticals,developmentofand

traininginStandardOperatingProceduresforEthicalReviewCommitteesinAsiaand

thewesternPacificregion.Co-editorandawriterofarticlesforThaiFDAandSafety

BulletinofHealthProductsJournals.Consultantonregistrationrequirementsforphar-

maceuticalproductsduringresearchanddevelopment.Proceedingonreductionand

phase-outofpharmaceuticalproducts(MeteredDoseInhalers)containingCFC.Survey

andevaluationofSIDCER-FERCAPqualityonethicalreviewprocessofIEC/IRBcommit-

tee.InspectionandevaluationofmanufacturingplantsforGMPCompliance.Traineron

qualitymanagement,processvalidationandgoodlaboratorypractice.

59

Name: Mr. Paul Vincke

Institution: EuropeanHealthcareFraudandCorruptionNetwork(EHFCN)

Country: Belgium

PaulVinckewasTreasurerandDeputyDirector-GeneralfromOctober2005,beforebe-

ingnominatedPresidentoftheEuropeanHealthcareFraudandCorruptionNetworkin

October2007.

Inthisnewfunctionhewishestocontinuehiseffortsbycommittinghimselffully

toestablishingaNetworktoberecognizedandappreciatedforplayinganimportant

roleandprovidingrealaddedvalueincounteringfraudandcorruptioninhealthcare

inEuropeandelsewhere.

By profession Paul Vincke is Director of Staff at the Service of Medical Evalua-

tionandControl(SECM)oftheNationalInstituteforHealthandDisabilityInsurance,

Belgium(INAMI).

HehasadegreeinCriminologyfromtheKatholiekeUniversiteitLeuven.

AfterbeingwiththeNationalPensionfundforMinersasaFinancialandPersonnel

Directorfor14years,hejoinedtheSECMoftheINAMIin1999becomingDirectorof

Staffresponsibleforpersonnel,organizationandgeneralpolicy.Asamemberofthe

managementteamheisdirectlyinvolvedinthereorganizationoftheService,aiming

atthedevelopmentofhighlyefficientsystemsandtoolsofevaluation,prevention,

detectionandinvestigationofallegedimproperuseoftheFederalhealthcareresources

byhealthcareproviders.Thisshouldresultinactivesurveillanceofgoodmedicalprac-

ticeandtheimpositionofappropriatesanctions.

60

Name: Mr. Eshetu Wondemagegnehu

Institution: WorldHealthOrganizationGGMGlobalAdvisoryGroup

Country: Ethiopia

MrEshetuWondemagegnehuisanEthiopianbynationality.HeholdsB.Pharm.andMSc

degreesinPharmacyandPharmaceuticalQualityControlrespectively.Hehasworkedfor

theEthiopianGovernmentindifferentcapacities,includingasheadoftheDrugControl

andToxicologyLaboratoryattheInstituteofPasteurinAddisAbaba,Ethiopia,forover

nineyearsandasheadoftheDrugControlDepartmentoftheMinistryofHealthofEthiopia

for12years.From1993to2006heworkedforWHO,Geneva,asaTechnicalOfficerinthe

DepartmentofEssentialDrugsandMedicines(EDM).

WhileatWHO,MrEshetu’smainworkwasbuildingmedicineregulatorycapacityand

training regulatoryofficers inAfrica,AsiaandotherWHOregions;collaborating in the

developmentofWHOnormsandguidelinesforensuringthequality,safetyandefficacyof

medicines;carryingoutoperationalresearchtoassessthestatusofmedicinesregulationin

MemberStates;developingWHOpolicydocumentsintheareaofmedicineregulationand

qualityassurance;promotingsub-regionalandregionalharmonizationofmedicineregula-

tion;combatingcounterfeitandsubstandardmedicines;trainingmedicineregulatorsand

otherlawenforcementauthoritiesondetectionandinvestigationofcounterfeitmedicines;

enhancinginter-country,regionalandinterregionaltechnicalcooperationtopromoteef-

fectivedrugregulation;developingtoolsforassessingmedicineregulationbettermanage-

mentandimplementationofqualityassuranceandregulatorymechanisms;andpromoting

awarenessamongthepublic,highleveldecision-makersandpoliticians,healthprofession-

als,etc.oftheneedforeffectivemedicineregulation.MrEshetuhasalsobeenactivein

conductingfieldstudiesandinthepublicationofWHOguidelinesanddocuments.

Inconnectionwithhisworkhehastravelledtoover60countriesinAfrica,Asia,Eu-

rope,NorthAmericaandthePacifictoorganizetrainingcourses,providetechnicalsupport

andmakepresentationsonissuesrelatedtoeffectivemedicineregulationandcounterfeit

medicines.

AtpresentheworksasaPharmaceuticalConsultant.HeisalsoamemberoftheWHO

ExpertCommitteeonSpecificationsforPharmaceuticalPreparationsandtheGGMGlobal

AdvisoryGroup.

EVALUATIONFORM

64

Evaluation Form Yourexperienceatthisstakeholdersmeetingisimportanttous.Pleasetakeafewmo-

mentstocompletethefollowingevaluationtogiveusyourviewsonthemeetingand

whatwecandobetteratfuturemeetings.

Name

Institution

Panel Sessions and PanellistsForthesessionsyouattended,please

• indicatehowinteresting/relevantthesessioncontentswasforyou/yourinstitution

4=Veryhigh 3=High 2=Good 1=Low

• ratethevalueofthepresentationsandparticipationofthepanellistswithineachsession

4=Excellent 3=Verygood 2=Good 1=Poor

PanelSession1:Thinktransparency!GoodGovernanceinthepharmaceuticalsector.

Overallvalueofthepanelsession 4321

Valueofthepresentationandparticipationofthepanellist

Dr.GuitelleBaghdadi-Sabeti,WHO,Switzerland 4321

Dr.ChanvitTharathep,MinistryofPublicHealth,Thailand 4321

Mr.ChangyuanLin,StateFoodandDrugAdministration,China 4321

Mrs.GerganaAndre,InternationalHealthcare 4321

andHealthInsuranceInstitute,Bulgaria

65

PanelSession2:Therootofcorruption.Understandingtheissuestocureit!



Dr.MaureenLewis,WorldBank 4321

Mr.MartinKreutner,BureauofInternationalAffairs, 4321

FederalMinistryofInterior,Austria

TransparencyInternationalSecretariat 4321

Dr.StevenRood,AsiaFoundation,Philippines 4321

PanelSession3:Practicingtransparency!GoodGovernanceinthehealthsector.



Dr.MaureenLewis,WorldBank 4321

Mr.JimGee,KPMGForensic,UnitedKingdom 4321

Mr.PaulVincke,EuropeanHealthcareFraudand 4321

CorruptionNetwork(EHFCN),Belgium

Dr.EricNoehrenberg,InternationalFederationof 4321

PharmaceuticalManufacturers&Associations

66

PanelSession4:Keepingittogether!ThebasicingredientsforensuringGoodGovernance.



Dr.EloyAnello,NùrUniversity,Bolivia 4321

Dr.SonjaFüsser,MinistryofHealth,Germany 4321

Mrs.FatumaSichale,Anti-CorruptionCommission,Kenya 4321

PanelSession5:Questioningtransparency.Ourpanellistsrespondtoyou!

Overallvalueofthesession 4321

PanelSession6:Rollingouttransparency.Whatisyourrole?


Valueofthepresentationandparticipationofthepanellist: 4321

Mr.AnthonyBoni,USAID,UnitedStatesofAmerica 4321

Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines 4321

Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand 4321

Dr.ZafarMirza,WHORegionalOfficeforthe 4321

EasternMediterranean,Egypt

67

WorkshopsFortheworkshopsessionsyouattended,pleaseindicatehowinteresting/relevantthesession

topicanddiscussionwasforyou/yourinstitution

4=Veryhigh3=High2=Good1=Low

1.BRIDGINGTHERESEARCHGAP–

whatdowestillneedtoknow,andhowdowegoaboutit? 4321

2.MAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY

how? 4321

3.ESTABLISHINGANATIONALGGMTASKFORCE

whatarethechallengesahead? 4321

4.JOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES

whatworks,whatdoesn’t? 4321

5.CANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?

howdowebringtransparencytothegreyzone? 4321

6.DEFININGINTEGRITY

howdoweraisethestandardsandmotivatepermanentchange? 4321

7.WHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?

whoaretheplayers?whatwillbetheimpactonpublichealth? 4321

8.SERVINGTRANSPARENCY!

HowcanWHObeofbetterservicewhenfacilitatingGGMprogramme

implementation?Giveyourideasandfeedback. 4321

68

Ratethefollowingaspectsofthemeeting

4=Excellent 3=Verygood 2=Good 1=Poor

Overallvalueofthemeeting 4321

Meetingagenda 4321

Networkingevents 4321

Location 4321

Hotelvenue 4321

Questions:

Whatpanelsessionsandworkshoptopicswouldyouliketoseeatthenextstake-

holdersmeeting?

Howcouldthenextmeetingbeabetterandmorevaluableresourceforyou?

DoyouintendtoattendthenextWHOstakeholdersmeeting? Yes/No

69

Anyadditionalfeedbackorcomments?

Thankyousomuchforyourtime,itisappreciated!

72

NOTES

73

NOTES

74

NOTES

75

NOTES

76

NOTES

77

NOTES

78

NOTES

79

NOTES

80

NOTES

81

NOTES

82

NOTES

83

NOTES

84

WHO'sGoodGovernanceforMedicinesprogrammewaslaunchedin2004.Itiscurrentlyoperatinginnineteencountriesglobally.Theprogramme'sgoal istoreducecorrup-tion inpharmaceuticalsystemsthroughtheapplicationoftransparent,accountableadministrativeproceduresandthepromotionofethicalpractices.Itsultimateaimistoensurethatessentialmedicinesreachpeople–nottheblackmarket.

WHOisgratefultotheGermanFederalMinistryforEconomicCooperationandDevelop-ment(BMZ)foritsfinancialsupport,withoutwhichthismeetingcouldnothavebeenheld. Additionalinformation:http://www.who.int/medicines/ggm [email protected]

MEETING GUIDE - WHO | World Health Organization · MEETING GUIDE. CONTENTS Welcome to ... •...

Documents

Transcript of MEETING GUIDE - WHO | World Health Organization · MEETING GUIDE. CONTENTS Welcome to ... •...